Goldman Sachs Group Inc Vaxxinity, Inc. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$1.43 - $4.24 $136,672 - $405,238	95,575 New	95,575 $216,000
Q1 2023 May 11, 2023	BUY	$1.43 - $4.24 $136,672 - $405,238	95,575 New	95,575 $216,000
Q2 2022 Aug 15, 2022	SELL	$1.55 - $6.95 $150,456 - $674,629	-97,069 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.7 - $8.6 $458,914 - $1.07 Million	-124,031 Reduced 56.1%	97,069 $417,000
Q4 2021 Feb 14, 2022	BUY	$5.55 - $18.46 $1.23 Million - $4.08 Million	221,100 New	221,100 $1.24 Million

287K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $1.12M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.